Why Choose Serum Cystatin C Levels over Serum Creatinine Levels as a Serologic Marker of Kidney Function?
Authors: Iddo Z. Ben-Dov
Journal: Annals of Internal Medicine (2008)

Letters19 August 2008Why Choose Serum Cystatin C Levels over Serum Creatinine Levels as a Serologic Marker of Kidney Function?Iddo Z. Ben-Dov, MD, MScIddo Z. Ben-Dov, MD, MScFrom Hadassah University Medical Center, 91120 Jerusalem, Israel.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-4-200808190-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their recent article, Kestenbaum and colleagues (1) reported that the incidence of hypertension in individuals without evident kidney disease is associated with variations in kidney function assessed by cystatin C levels. This implicates covert kidney dysfunction in the pathogenesis of hypertension. I wish to address issues concerning surrogates of clinical disease.The authors excluded participants with overt kidney disease, defined by reduced creatinine level–based estimated glomerular filtration rate (GFR). However the outcome analyses were conducted by using serum cystatin C levels. Would the results materially differ if serum creatinine levels or estimated GFR rates had been ...References1. Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med. 2008;148:501-8. [PMID: 18378946] LinkGoogle Scholar2. Ben-Dov IZ, Ben-Arie L, Mekler J, Bursztyn M. In clinical practice, masked hypertension is as common as isolated clinic hypertension: predominance of younger men. Am J Hypertens. 2005;18:589-93. [PMID: 15882539] CrossrefMedlineGoogle Scholar3. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-74. [PMID: 16738273] CrossrefMedlineGoogle Scholar4. Ben-Dov IZ, Kark JD, Mekler J, Shaked E, Bursztyn M. The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. J Hypertens. 2008;26:699-705. [PMID: 18327079] CrossrefMedlineGoogle Scholar5. Matsui Y, Eguchi K, Ishikawa J, Hoshide S, Shimada K, Kario K. Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. Am J Hypertens. 2007;20:385-91. [PMID: 17386344] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hadassah University Medical Center, 91120 Jerusalem, Israel.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDifferences in Kidney Function and Incident Hypertension: The Multi-Ethnic Study of Atherosclerosis Bryan Kestenbaum , Kyle D. Rudser , Ian H. de Boer , Carmen A. Peralta , Linda F. Fried , Michael G. Shlipak , Walter Palmas , Catherine Stehman-Breen , and David S. Siscovick Why Choose Serum Cystatin C Levels over Serum Creatinine Levels as a Serologic Marker of Kidney Function? Bryan Kestenbaum Metrics Cited BySerum cystatin C and anti- N -methyl-D-aspartate receptor encephalitisNovel Kidney Injury Biomarkers 19 August 2008Volume 149, Issue 4Page: 284KeywordsBlood pressureCohort studiesConflicts of interestCreatinineHypertensionKidneysPathogenesisRenal diseasesSpecificity ePublished: 19 August 2008 Issue Published: 19 August 2008 CopyrightCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...